{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T03:02:19Z","timestamp":1781578939960,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40257-022-00720-0","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T12:05:44Z","timestamp":1660305944000},"page":"813-822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Deucravacitinib for the Treatment of Psoriatic Disease"],"prefix":"10.1007","volume":"23","author":[{"given":"Ana Maria","family":"L\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Luis","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"issue":"19","key":"720_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA J Am Med Assoc. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006.","journal-title":"JAMA J Am Med Assoc"},{"issue":"5","key":"720_CR2","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1080\/09546634.2020.1746734","volume":"31","author":"S Gerdes","year":"2020","unstructured":"Gerdes S, K\u00f6rber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. J Dermatol Treat. 2020;31(5):470\u20135. https:\/\/doi.org\/10.1080\/09546634.2020.1746734.","journal-title":"J Dermatol Treat"},{"issue":"12","key":"720_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052935","volume":"7","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation Survey Data 2003\u20132011. PLoS\u00a0One. 2012;7(12): e52935. https:\/\/doi.org\/10.1371\/journal.pone.0052935.","journal-title":"PLoS\u00a0One"},{"issue":"6","key":"720_CR4","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605\u201313. https:\/\/doi.org\/10.4049\/jimmunol.1800013.","journal-title":"J Immunol"},{"key":"720_CR5","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/ijlh.12426","volume":"31","author":"G Girolomoni","year":"2017","unstructured":"Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23\/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1616\u201326. https:\/\/doi.org\/10.1111\/ijlh.12426.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"720_CR6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","volume":"140","author":"JE Hawkes","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645\u201353. https:\/\/doi.org\/10.1016\/j.jaci.2017.07.004.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"720_CR7","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1038\/jid.2012.167","volume":"132","author":"J Bergboer","year":"2012","unstructured":"Bergboer J, Zeeuwen P, Schalkwijk J. Genetics of psoriasis: evidence for epistatic interaction between skin barrier abnormalities and immune deviation. J Investig Dermatol. 2012;132(10):2320\u201331. https:\/\/doi.org\/10.1038\/jid.2012.167.","journal-title":"J Investig Dermatol"},{"issue":"9997","key":"720_CR8","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"W Boehncke","year":"2015","unstructured":"Boehncke W, Sch\u00f6n MP. Psoriasis. Lancet. 2015;386(9997):983\u201394. https:\/\/doi.org\/10.1016\/S0140-6736(14)61909-7.","journal-title":"Lancet"},{"issue":"3","key":"720_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1468-3083.2012.04644.x","volume":"27","author":"S Dogra","year":"2013","unstructured":"Dogra S, Jain A, Kanwar AJ. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50\u00a0mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study. J Eur Acad Dermatol Venereol. 2013;27(3):305\u201311. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04644.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"720_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, Kircik L, Griffiths CEM. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Dermatol. 2015;73(1):37\u201349. https:\/\/doi.org\/10.1016\/j.jaad.2015.03.049.","journal-title":"J Am Dermatol"},{"issue":"10068","key":"720_CR11","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0140-6736(16)32127-4","volume":"389","author":"RB Warren","year":"2016","unstructured":"Warren RB, Mrowietz U, Von KR, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2016;389(10068):528\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(16)32127-4.","journal-title":"Lancet"},{"issue":"5","key":"720_CR12","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jaad.2009.05.017","volume":"62","author":"DM Rosmarin","year":"2010","unstructured":"Rosmarin DM, Lebwohl M, Elewski BE, Gottlieb AB. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation * Consensus Conference. J Am Dermatol. 2010;62(5):838\u201353. https:\/\/doi.org\/10.1016\/j.jaad.2009.05.017.","journal-title":"J Am Dermatol"},{"issue":"June","key":"720_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/ddr.21263","volume":"76","author":"T Torres","year":"2015","unstructured":"Torres T, Filipe P. Small molecules in the treatment of psoriasis. Drug Dev Res. 2015;76(June):215\u201327. https:\/\/doi.org\/10.1002\/ddr.21263.","journal-title":"Drug Dev Res"},{"issue":"1","key":"720_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00649-w","volume":"23","author":"AM Le","year":"2022","unstructured":"Le AM, Torres T. New topical therapies for psoriasis. Am J Clin Dermatol. 2022;23(1):13\u201324. https:\/\/doi.org\/10.1007\/s40257-021-00649-w.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"720_CR15","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521\u201346. https:\/\/doi.org\/10.1007\/s40265-017-0701-9.","journal-title":"Drugs"},{"issue":"1","key":"720_CR16","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","volume":"228","author":"K Ghoreschi","year":"2009","unstructured":"Ghoreschi K, Laurence A, O\u2019Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273\u201387. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00754.x.","journal-title":"Immunol Rev"},{"key":"720_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.11.001","author":"IM Catlett","year":"2021","unstructured":"Catlett IM, Hu Y, Gao L, Banerjee S, Gordon K, Krueger JG. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2021. https:\/\/doi.org\/10.1016\/j.jaci.2021.11.001.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"720_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","volume":"93","author":"SJ Rodig","year":"1998","unstructured":"Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998;93(3):373\u201383. https:\/\/doi.org\/10.1016\/S0092-8674(00)81166-6.","journal-title":"Cell"},{"issue":"13992","key":"720_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms13992","volume":"7","author":"D Eletto","year":"2016","unstructured":"Eletto D, Burns SO, Angulo I, et al. Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection. Nat Commun. 2016;7(13992):1\u201312. https:\/\/doi.org\/10.1038\/ncomms13992.","journal-title":"Nat Commun"},{"issue":"3","key":"720_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0059675","volume":"8","author":"SO Park","year":"2013","unstructured":"Park SO, Wamsley HL, Bae K, et al. Conditional deletion of Jak2 reveals an essential role in hematopoiesis throughout mouse ontogeny: implications for Jak2 inhibition in humans. PLoS\u00a0One. 2013;8(3):1\u201313. https:\/\/doi.org\/10.1371\/journal.pone.0059675.","journal-title":"PLoS\u00a0One"},{"issue":"5237","key":"720_CR21","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1126\/science.270.5237.800","volume":"270","author":"T Nosaka","year":"1995","unstructured":"Nosaka T, Van Deursen JMA, Tripp RA, et al. Defective lymphoid development in mice lacking Jak3. Science. 1995;270(5237):800\u20132. https:\/\/doi.org\/10.1126\/science.270.5237.800.","journal-title":"Science"},{"issue":"4","key":"720_CR22","first-page":"7","volume":"270","author":"SM Russell","year":"1995","unstructured":"Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science. 1995;270(4):7\u201310.","journal-title":"Science"},{"key":"720_CR23","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.biocel.2009.09.004","volume":"41","author":"MG Cornejo","year":"2009","unstructured":"Cornejo MG, Boggon TJ, Mercher T. The International Journal of Biochemistry JAK3: a two-faced player in hematological disorders. Int J Biochem Cell Biol. 2009;41:2376\u20139. https:\/\/doi.org\/10.1016\/j.biocel.2009.09.004.","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"720_CR24","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Park SH, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1133\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207319.","journal-title":"Ann Rheum Dis"},{"key":"720_CR25","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519\u201331. https:\/\/doi.org\/10.2147\/JIR.S219586.","journal-title":"J Inflamm Res"},{"issue":"11","key":"720_CR26","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","volume":"79","author":"P Mease","year":"2020","unstructured":"Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216761.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"720_CR27","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaad.2017.03.023","volume":"77","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77(2):302\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2017.03.023.","journal-title":"J Am Acad Dermatol"},{"key":"720_CR28","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","volume":"173","author":"KA Papp","year":"2015","unstructured":"Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949\u201361. https:\/\/doi.org\/10.1111\/bjd.14018.","journal-title":"Br J Dermatol"},{"key":"720_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15361","author":"Z Dong","year":"2022","unstructured":"Dong Z, Ye X, Chen C, Wang R, Liu D, Xu X, Zhou X. Thromboembolic events in Janus kinase inhibitors: a pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration\u2019s Adverse Event Reporting System. Br J Clin Pharmacol. 2022. https:\/\/doi.org\/10.1111\/bcp.15361(Epub ahead of print).","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"720_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","volume":"80","author":"M Nogueira","year":"2020","unstructured":"Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs. 2020;80(4):341\u201352. https:\/\/doi.org\/10.1007\/s40265-020-01261-8.","journal-title":"Drugs"},{"key":"720_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1126\/scitranslmed.aag1974","volume":"8","author":"CA Dendrou","year":"2016","unstructured":"Dendrou CA, Cortes A, Shipman L, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016;8:363. https:\/\/doi.org\/10.1126\/scitranslmed.aag1974.","journal-title":"Sci Transl Med"},{"issue":"10","key":"720_CR32","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1084\/jem.20140280","volume":"212","author":"AY Kreins","year":"2015","unstructured":"Kreins AY, Ciancanelli MJ, Okada S, et al. Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med. 2015;212(10):1641\u201362. https:\/\/doi.org\/10.1084\/jem.20140280.","journal-title":"J Exp Med"},{"issue":"6","key":"720_CR33","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.jpeds.2012.01.056","volume":"160","author":"SS Kilic","year":"2012","unstructured":"Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr. 2012;160(6):1055\u20137. https:\/\/doi.org\/10.1016\/j.jpeds.2012.01.056.","journal-title":"J Pediatr"},{"key":"720_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15605","author":"CE Jo","year":"2021","unstructured":"Jo CE, Gooderham M, Beecker J. Review treatment of dermatologic conditions: the evolution of JAK inhibitors. Int J Dermatol. 2021. https:\/\/doi.org\/10.1111\/ijd.15605.","journal-title":"Int J Dermatol"},{"issue":"11","key":"720_CR35","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/ng.694","volume":"42","author":"A Strange","year":"2010","unstructured":"Strange A, Capon F, Spencer CCA, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet. 2010;42(11):985\u201390. https:\/\/doi.org\/10.1038\/ng.694.","journal-title":"Nat Genet"},{"issue":"5","key":"720_CR36","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","volume":"11","author":"A Chimalakonda","year":"2021","unstructured":"Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with janus kinase 1\/2\/3 inhibitors. Dermatol Ther (Heidelb). 2021;11(5):1763\u201376. https:\/\/doi.org\/10.1007\/s13555-021-00596-8.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"720_CR37","unstructured":"Gillooly K, Zhang Y, Yang X, Zupa-Fernandez A, Cheng L, Strnad J, Cunningham M, Heimrich E, Zhou X, Chen J, Chaudhry C, Li S, McIntyre K, Carman J, Moslin R, Wrobleski S, Weinstein D, Burke J.Gillooly K, Zhang Y, Yang X, Zupa-Fernandez A, Cheng L, Strnad BJ. BMS-986165 is a highly potent and selective allosteric inhibitor of Tyk2, blocks IL-12, IL-23 and type I interferon signaling and provides for robust efficacy in preclinical models of systemic lupus erythematosus and inflammatory bowel disease. Arthritis Rheumatol. 2016;68(Suppl 10). https:\/\/acrabstracts.org\/abstract\/bms-986165-is-a-highly-potent-and-selective-allosteric-inhibitor-of-tyk2-blocks-il-12-il-23-and-type-i-interferon-signaling-and-provides-for-robust-efficacy-in-preclinical-models-of-systemic-lupus-e\/. Accessed Oct 5."},{"issue":"17","key":"720_CR38","doi-asserted-by":"publisher","first-page":"11061","DOI":"10.1074\/jbc.M114.619502","volume":"290","author":"JS Tokarski","year":"2015","unstructured":"Tokarski JS, Zupa-Fernandez A, Tredup JA, et al. Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain. J Biol Chem. 2015;290(17):11061\u201374. https:\/\/doi.org\/10.1074\/jbc.M114.619502.","journal-title":"J Biol Chem"},{"issue":"62","key":"720_CR39","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","volume":"2","author":"ST Wrobleski","year":"2019","unstructured":"Wrobleski ST, Moslin R, Lin S, et al. Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J Med Chem. 2019;2(62):8973\u201395. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00444.","journal-title":"J Med Chem"},{"key":"720_CR40","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2017-eular.3036","volume":"76","author":"I Catlett","year":"2017","unstructured":"Catlett I, Aras U, Liu Y, Bei D, et al. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2 [abstract]. Ann Rheum Dis. 2017;76:859. https:\/\/doi.org\/10.1136\/annrheumdis-2017-eular.3036.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"720_CR41","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/cpdd.1056","volume":"11","author":"A Chimalakonda","year":"2022","unstructured":"Chimalakonda A, Singhal S, Darbenzio R, et al. Lack of electrocardiographic effects of deucravacitinib in healthy subjects. Clin Pharmacol Drug Dev. 2022;11(4):442\u201353. https:\/\/doi.org\/10.1002\/cpdd.1056.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"720_CR42","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"K Papp","year":"2018","unstructured":"Papp K, Gordon K, Tha\u00e7i D, Morita A, Gooderham M, Foley P, Girgis IG, Kundu SBS. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379:1313\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1806382.","journal-title":"N Engl J Med"},{"key":"720_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00649-y","author":"D Tha\u00e7i","year":"2022","unstructured":"Tha\u00e7i D, Strober B, Gordon KB, Foley P, Gooderham M, Morita A, Papp KA, Puig L, Menter MA, Colombo MJ, Elbez Y, Kisa RM, Ye J, Napoli AA, Wei L, Banerjee S, Merola JF, Gottlieb AB. Deucravacitinib in moderate to severe psoriasis: clinical and quality-of-life outcomes in a phase 2 trial. Dermatol Ther. 2022. https:\/\/doi.org\/10.1007\/s13555-021-00649-y(Epub ahead of print).","journal-title":"Dermatol Ther"},{"key":"720_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.07.002","author":"AW Armstrong","year":"2022","unstructured":"Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2022. https:\/\/doi.org\/10.1016\/j.jaad.2022.07.002.","journal-title":"J Am Acad Dermatol"},{"key":"720_CR45","doi-asserted-by":"crossref","unstructured":"Warren R, Armstrong A, Gooderham M, Strober B, et al. Abstract No 2857\u2014deucravacitinib, an oral , selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. EADV 30th Congr. Published online 2021:1\u20132. https:\/\/s3.eu-central-1.amazonaws.com\/cst.eadv\/eadv2021\/abstracts\/26128.html.pdf","DOI":"10.1136\/annrheumdis-2022-eular.1377"},{"key":"720_CR46","doi-asserted-by":"crossref","unstructured":"Lebwohl M, Gooderham M, Warren RB, et al. Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: achievement of absolute PASI thresholds in the phase 3 POETYK PSO-1 and PSO-2 trials [poster]. Am Acad Dermatology Annu Meet March 25\u201329 2022, Boston.","DOI":"10.1016\/j.jaad.2022.06.199"},{"key":"720_CR47","unstructured":"Blauvelt A, Rich P, Sofen H, et al. Abstract No 999\u2014deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, versus placebo and apremilast in scalp psoriasis: analysis of the phase 3 POETYK PSO-1 and POETYK PSO-2 trials. EADV 30th Congr. Published online 2021. https:\/\/s3.eu-central-1.amazonaws.com\/cst.eadv\/eadv2021\/abstracts\/24270.html.pdf."},{"key":"720_CR48","doi-asserted-by":"crossref","unstructured":"Armstrong A, Strober B, Gordon KB, et al. Abstract N\u00b0:2127\u2014deucravacitinib improves psoriasis symptoms and signs diary domain scores in patients with moderate to severe plaque psoriasis: results from the phase 3 POETYK PSO-1 and POETYK PSO-2 studies. EADV 30th Congr. https:\/\/s3.eu-central-1.amazonaws.com\/cst.eadv\/eadv2021\/abstracts\/25398.html.pdf.","DOI":"10.25251\/skin.5.supp.38"},{"key":"720_CR49","doi-asserted-by":"crossref","unstructured":"Tha\u00e7i D, Gordon KB, Gooderham M, et al. Abstract N\u00b0: 1108\u2014deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, compared with placebo and apremilast in moderate to severe plaque psoriasis: integrated laboratory parameter results from the phase 3 POETYK PSO-1 and POETYK PSO-2. EADV 30th Congr. Published online 2021. https:\/\/s3.eu-central-1.amazonaws.com\/cst.eadv\/eadv2021\/abstracts\/24379.html.pdf.","DOI":"10.25251\/skin.5.supp.37"},{"key":"720_CR50","unstructured":"Warren RB, Sofen H, Imafuku S, et al. Poster\u2014Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. In: Presented at European Academy of Dermatology and Venereology (EADV) Spring Symposium."},{"key":"720_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221664","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Deodhar AA, van der Heijde D, et al. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221664.","journal-title":"Ann Rheum Dis"},{"key":"720_CR52","doi-asserted-by":"crossref","unstructured":"Mease P, Deodhar A, van der Heijde D, Behrens F, Kivitz A, Kim J, Singhal S, Nowak M, Barnerjee S. Efficacy and safety of deucravacitinib (BMS-986165), an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial [abstract]. Arthritis Rheumatol. 2020;72(10). https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-deucravacitinib-bms-986165-an-oral-selective-tyrosine-kinase-2-inhibitor-in-patients-with-active-psoriatic-arthritis-results-from-a-phase-2-randomized-double-blind-plac\/. Accessed Dec 22, 2021.","DOI":"10.1136\/annrheumdis-2021-eular.2603"},{"key":"720_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.05.016","author":"KB Gordon","year":"2019","unstructured":"Gordon KB, Armstrong AW, Foley P, et al. Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study. J Investig Dermatol. 2019. https:\/\/doi.org\/10.1016\/j.jid.2019.05.016.","journal-title":"J Investig Dermatol"},{"issue":"2","key":"720_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/13543776.2019.1567713","volume":"29","author":"X He","year":"2019","unstructured":"He X, Chen X, Zhang H, Xie T, Ye XY. Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019\u20132021). Expert Opin Ther Pat. 2019;29(2):137\u201349. https:\/\/doi.org\/10.1080\/13543776.2019.1567713.","journal-title":"Expert Opin Ther Pat"},{"key":"720_CR55","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2008240","author":"A Abduelmula","year":"2021","unstructured":"Abduelmula A, Gooderham MJ. TYK2 inhibition: changing the treatment landscape for psoriasis? Expert Rev Clin Immunol. 2021. https:\/\/doi.org\/10.1080\/1744666X.2022.2008240.","journal-title":"Expert Rev Clin Immunol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00720-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00720-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00720-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:07:13Z","timestamp":1744715233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00720-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["720"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00720-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"25 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AML, LP and TT had the idea for the article, performed the literature search and data analysis, and drafted and critically revised the work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"No funding was received for the preparation of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"Ana Maria L\u00e9 has no conflicts of interest. Luis Puig has served as a scientific adviser and\/or clinical study investigator for, or has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, JS BIOCAD, LEO Pharma, Lilly, Mylan, Novartis, Pfizer, Regeneron, Roche, Sandoz, Samsung-Bioepis, Sanofi and UCB. Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz and UCB.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}